Key result
Sequential chemoradiation therapy in lung cancer patients significantly reduced FEV1 (P=0.012), FVC (P=0.046), TLC (P=0.04), DLCO (P=0.002), and KCO (P=0.008) from baseline.
Why the study?
Does sequential chemoradiation therapy reduce lung function in patients with lung cancer?
Observational (n=15)
Does sequential chemoradiation therapy reduce lung function in patients with lung cancer?
Sequential chemoradiation therapy causes significant reductions in lung function parameters in patients with lung cancer.
Answers are grounded in this paper and cite their sources.
Supports pulmonary surveillance in sequential chemoradiation; leaves open causality and mitigation strategies for randomized confirmation.
Background: Reports point out lung toxicity of chemotherapeutic agents and radiation therapy in cancer patients. The aim of our study was to assess lung function after sequential chemoradiation therapy in patients with lung cancer Methods: Fifteen lung cancer patients participated the study and underwent lung function assessment before and after sequential treatment of chemotherapy with the 3 most applied platinum-based combinations: of vinorelbine (VN) 6 patients, gemcitabine (GEM) 4 patients and etoposide (EP) 5 patients and radiation therapy. Lung function tests were forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), total lung capacity (TLC), diffusing capacity for carbon monoxide (DL CO ) and carbon monoxide transfer coefficient (Kco). Results: Mean patients’ age was 58±9.4 years (42–75 years). Male patients were 14 (93.3%), all smokers. Overall, after chemoradiation treatment significant changes were noted in FEV1 (P=0.012), FVC (P=0.046), TLC (P=0.04) from baseline. The drop from baseline was more significant after chemoradiation therapy in DLCO (P=0.002) and KCO (P=0.008). Conclusions: According to our results, sequential chemoradiation causes significant changes in lung function parameters in patients with lung cancer.
No takes yet. Share an insight, caveat, or question.
Mihailidis et al. (2018) conducted an observational in lung cancer (n=15). Sequential chemoradiation therapy vs. baseline was evaluated on Changes in lung function tests (FEV1, FVC, TLC, DLCO, KCO) from baseline (p=0.012). Sequential chemoradiation therapy in lung cancer patients significantly reduced FEV1 (P=0.012), FVC (P=0.046), TLC (P=0.04), DLCO (P=0.002), and KCO (P=0.008) from baseline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: